KEI comments to FDA on Prospective Exclusive Patent License for Diagnostic for SARS, SARS-CoV-2, Other Viruses, Bacteria and Bacterial Serovar, to Advion

To: Ken Millburne Technology Transfer Program Food and Drug Administration Via email: Kenneth.millburne@fda.hhs.gov From: James Love Knowledge Ecology International 1621 Connecticut Avenue NW, Suite 500 Washington, DC 20009 https://keionline.org Date: November 30, 2020 Re: Prospective Grant of an Exclusive Patent… Continue Reading

Regeneron $450 million contract with Advanced Technology International has Patent Rights Clause that Narrows Government Rights in Patented Inventions

A contract between Regeneron and Advanced Technology International (ATI) involving $450 million in taxpayer funding uses the “Other Transactions Authority” or OTA, to avoid Bayh-Dole safeguards on patent rights. ATI is entering into purchase agreements on behalf of the Department… Continue Reading

KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment

On July 7, 2020, Knowledge Ecology International (KEI) submitted comments to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the… Continue Reading

Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy

(Update: The NIH provided a response to our comments on July 16, 2020) On July 6, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment submitted joint comments regarding the National Institutes of Health’s (NIH) proposed exclusive license… Continue Reading

Joint Comments on Two NIH Exclusive Licenses to CAR Therapy to Vor Biopharma and Senti Bio

On June 15, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatments (UACT) submitted joint comments to the National Institutes of Health regarding two prospective exclusive patent licenses: “Prospective Grant of an Exclusive Patent License: Development and… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment

Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading

WHA73: Written statement of KEI – Agenda item 3 – Address by WHO Director-General devoted to the COVID-19 pandemic response in advance of the opening of the Health Assembly

KEI is an accredited non-state actor at the World Health Organization (WHO). This is our statement at the 73rd World Health Assembly. https://extranet.who.int/nonstateactorsstatements/meetingoutline/6 Knowledge Ecology International Meeting: Seventy-third World Health Assembly Written statements on COVID-19 pandemic The biggest question today… Continue Reading